Alleviant Medical Valuation, Funding & Investors

Alleviant Medical is valued at $260M as of January 2025.

Last Alleviant Medical valuation

$260M

Undisclosed stage · Jan 2025

Last Alleviant Medical funding round

$90M

Undisclosed stage · Jan 2025

Cumulative funding Alleviant Medical raised

$177M

across 3 funding rounds

Key investors in Alleviant Medical

  • S3 Ventures
  • RiverVest
  • Vensana Capital
  • TMC Venture Fund
  • Longview Ventures
  • Gilmartin Capital LLC

Alleviant Medical Overview

About Alleviant Medical

Alleviant Medical develops the Alleviant Heart Stabilizer, a transcatheter mitral valve repair device for congestive heart failure patients. Inserted via femoral artery access, the implant reshapes the mitral annulus to reduce regurgitation and improve cardiac output. Targeting the 6 million US heart failure cases, the system aims to cut hospital readmissions by 50 percent in clinical trials. Based in Tampa, Florida, the company raised Series A funding in 2021 and plans FDA pivotal studies.


Founded

2017

HQ

United StatesAustin, TX

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$260M (Jan 2025)

Alleviant Medical Valuation

Alleviant Medical is currently valued at $260M, based on its undisclosed-stage round in January 2025.

The $90M round was led by Gilde Healthcare, with participation from Gilmartin Capital LLC, S3 Ventures, Vensana Capital, RiverVest, Omega Funds and 2 other investors.

Alleviant Medical valuation by funding round

Alleviant Medical valuation by funding round
DateStageValuation
Jan 2025Undisclosed stage$260M

Alleviant Medical Funding History

Alleviant Medical has raised a total of $177M across 3 funding rounds.

Alleviant Medical's first fundraising round was a $13M Series A in May 2020. The most recent completed round was a $90M undisclosed-stage round in January 2025.

Alleviant Medical funding rounds

Alleviant Medical funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Jan 2025Undisclosed stageGilde Healthcare (lead); Gilmartin Capital LLC; S3 Ventures; Vensana Capital; RiverVest; Omega Funds; Longview Ventures; TMC Venture Fund$90M$260MAlleviant Medical is a privately held medical device company headquartered in Austin, Texas, developing minimally invasive therapies to treat heart failure. The company's flagship product is a no-implant atrial shunt system designed to alleviate excess pressure within the heart through a one-time procedure with no permanent implant remaining. The Alleviant System has received U.S. FDA Breakthrough Device designation for both major forms of heart failure: HFpEF (heart failure with preserved ejection fraction) and HFrEF (heart failure with reduced ejection fraction). On January 14, 2025, Alleviant Medical closed a Series D funding round of $90 million led by Gilde Healthcare. The round also included new investor Omega Funds and participation from existing shareholders S3 Ventures, RiverVest Venture Partners, Vensana Capital, Longview Ventures, Gilmartin Capital, TMC Venture Fund, and undisclosed strategic investors. The company was valued at $260.0 million post-money as of the funding date. Total capital raised across all rounds reached $189.1 million. The Series D funding will support the company's second pivotal clinical trial, ALLAY-HFrEF, which will be the first prospective sham-controlled trial focused on patients with heart failure and reduced ejection fraction in the atrial shunt space. This trial represents a significant de-risking of the clinical program and positions Alleviant to address a substantial market opportunity, as heart failure is a leading cause of mortality and hospitalizations in the United States, with estimated annual healthcare costs of $70 billion. CEO Adam Berman emphasized the company's commitment to developing effective, minimally invasive treatments for the full spectrum of chronic heart failure, supported by a syndicate of prominent healthcare investors.
Jan 2023Undisclosed stageRiverVest (lead); S3 Ventures (lead); Gilmartin Capital LLC; Vensana Capital; Shangbay Capital; Longview Ventures; TMC Venture Fund$74M-Alleviant Medical is a privately held medical device company developing a no-implant interatrial shunt for the treatment of heart failure. The company closed a $75 million Series C equity financing on January 26, 2023, co-led by S3 Ventures and RiverVest Venture Partners, with participation from Vensana Capital, Longview Ventures, TMC Venture Fund, and strategic investors. The financing was used to fund the company's pivotal clinical trial program, and the round coincided with FDA IDE (Investigational Device Exemption) approval for Alleviant's pivotal clinical trial. The company's total funding reached $189 million across all rounds.
May 2020Series ABroadview Ventures$13M-Alleviant Medical is a medical device company developing a no-implant interatrial shunt system for heart failure treatment. In 2020, Longview Ventures, an affiliate of Broadview Ventures, invested in the company's $20M Series B round to fund first-in-human and additional clinical studies. The round supported advancement of the Alleviant System, which has received U.S. FDA Breakthrough Device designation for heart failure. Broadview Ventures' portfolio, including Alleviant Medical, saw co-investments and follow-on financings totaling $318M across companies in 2020. Longview Ventures, a $100M fund for follow-on investments in select Broadview portfolio companies, participated in Alleviant Medical's Series B alongside its investment in AtaCor Medical's $25M Series B.

Who has invested in Alleviant Medical?

10 investors have backed Alleviant Medical across its funding rounds, including S3 Ventures, RiverVest, Vensana Capital, TMC Venture Fund, Longview Ventures and Gilmartin Capital LLC.

Lead investors include Gilde Healthcare, RiverVest and S3 Ventures.


Alleviant Medical Investors

Investors in Alleviant Medical by funding rounds participated
InvestorHQRoundsRoleFirst check
Gilmartin Capital LLCUnited StatesUnited States2ParticipantJan 2023
S3 VenturesUnited StatesAustin, TX2LeadJan 2023
Vensana CapitalUnited StatesMinneapolis, MN2ParticipantJan 2023
RiverVestUnited StatesUnited States2LeadJan 2023
Longview VenturesUnited StatesBoston, MA2ParticipantJan 2023
TMC Venture FundUnited StatesHouston, TX2ParticipantJan 2023
Broadview VenturesUnited StatesBoston, MA1ParticipantMay 2020
Shangbay CapitalUnited StatesSan Francisco, CA1ParticipantJan 2023

This data is available for Pro users. Sign up to see all 10 Alleviant Medical investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Alleviant Medical Competitors

Alleviant Medical competitors include listed companies like Tess Holdings Co, Medipost and Dong-A ST, and private ones like Unlearn.AI, Restor3d and Convergent Therapeutics.

Public and private companies comparable to Alleviant Medical
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Tess Holdings CoJapanJapanPublicly listed$236M$37M$262M2.2x
Unlearn.AIUnited StatesSan Francisco, CAPrivate--$265M-
MedipostSouth KoreaSouth KoreaPublicly listed$54M($59M)$255M4.7x
Restor3dUnited StatesDurham, NCPrivate--$266M-
Convergent TherapeuticsUnited StatesUnited StatesPrivate--$269M-
Dong-A STSouth KoreaSouth KoreaPublicly listed$589M$6M$251M0.8x

Alleviant Medical Public Comps

Alleviant Medical is still privately-owned, but its public comps include Tess Holdings Co, Surgical Science, Medipost, Dong-A ST, InfuSystem, Anbio Biotechnology, NN, OraSure, Anika Therapeutics and Eurobio Scientific.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Tess Holdings Co$236M$37M3.1x2.2x19.8x-
Surgical Science$101M$18M1.9x1.9x11.2x9.4x
Medipost$54M($59M)4.3x4.7x(3.9x)(9.7x)
Dong-A ST$589M$6M0.8x0.8x84.0x10.1x
InfuSystem$143M$25M1.9x1.9x10.7x8.5x
Anbio Biotechnology$9M$6M26.8x-37.1x-
NN$422M$17M1.4x1.3x34.5x10.5x
OraSure$115M($55M)0.8x0.8x(1.7x)(2.2x)

This data is available for Pro users. Sign up to see all Alleviant Medical competitors and their valuation data.

Start Free Trial

Common questions about Alleviant Medical

When was Alleviant Medical founded?Alleviant Medical was founded in 2017.
Where is Alleviant Medical headquartered?Alleviant Medical is headquartered in Austin, TX, United States.
Is Alleviant Medical publicly listed?No, Alleviant Medical is a private, VC-backed company.
What is Alleviant Medical's valuation?Alleviant Medical was last valued at $260M in its undisclosed-stage round in January 2025.
How much funding has Alleviant Medical raised?Alleviant Medical has raised $177M across 3 funding rounds.
What was Alleviant Medical's last funding round?Alleviant Medical's last funding round was a $90M undisclosed-stage round in January 2025, led by Gilde Healthcare.
Who are Alleviant Medical's investors?Alleviant Medical's investors include Gilmartin Capital LLC, S3 Ventures, Vensana Capital, RiverVest, Longview Ventures, TMC Venture Fund, Broadview Ventures, Shangbay Capital, Gilde Healthcare and Omega Funds.
Which companies are comparable to Alleviant Medical?Companies comparable to Alleviant Medical include Tess Holdings Co, Unlearn.AI, Medipost, Restor3d, Convergent Therapeutics and Dong-A ST.

See companies similar to Alleviant Medical

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial